Acumen Doses First Patient in Alzheimer’s Disease Trial
Acumen Pharmaceuticals (Nasdaq: ABOS) has dosed the first patient in its Phase 2, multi-center, randomized, double-blind, placebo-controlled clinical trial evaluating sabirnetug (ACU193) as a treatment for Alzheimer’s disease (AD). Sabirnetug, a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs), has been granted FDA Fast Track designation and was previously evaluated in a Phase 1 study in patients with early AD.
“Today marks a significant milestone for Acumen and the Alzheimer’s community as we begin the Phase 2 trial of sabirnetug,” said Daniel O’Connell, Chief Executive Officer of Acumen. “Sabirnetug is at the forefront of the next generation of Alzheimer’s therapies, with encouraging Phase 1 results supporting its novel mechanism of action and selectivity for toxic amyloid beta oligomers. These results have led to a high level of investigator and patient interest in sabirnetug’s therapeutic potential and a strong start to the trial.”
Acumen’s global ALTITUDE-AD study will enroll approximately 540 individuals at sites in the US, Canada, the UK and Europe and will evaluate the efficacy and safety of sabirnetug (ACU193) infusions in slowing cognitive and functional decline as compared to placebo in participants with early Alzheimer’s disease.
The company also plans to conduct a Phase 1 bioavailability study to support subcutaneous dosing of sabirnetug, and expects the study to commence in mid-2024.
About Acumen Pharmaceuticals, Inc.
Acumen, headquartered in Charlottesville, VA, with additional offices in Indianapolis, IN and Newton, MA, is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD). Acumen’s scientific founders pioneered research on AβOs, which a growing body of evidence indicates are early and persistent triggers of Alzheimer’s disease pathology. Acumen is currently focused on advancing its investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody that selectively targets toxic soluble AβOs, following positive results in INTERCEPT-AD, a Phase 1 clinical trial involving early Alzheimer’s disease patients. For more information, visit www.acumenpharm.com.
